The House passed the Sunshine Protection Act (H.R. 139) on July 14, 2026, by a 308-117 bipartisan vote, advancing permanent daylight saving time with state opt-out provisions and receiving President Trump's endorsement. The measure was referred to the Senate Commerce Committee the next day, where the companion bill remains stalled without further action. Historical precedent shows repeated congressional failures despite similar momentum, compounded by sleep medicine opposition citing circadian health risks and a compressed legislative calendar before the end of 2026. Trader consensus reflected in the 72.5% "No" probability accounts for these Senate procedural and timing barriers, even as 19 states maintain conditional statutes awaiting federal authorization.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$13,137 Vol.
$13,137 Vol.
$13,137 Vol.
$13,137 Vol.
The existence of any carve-outs or exceptions shall not be relevant for purposes of this market.
The primary resolution source is Congress.gov’s legislation tracker (https://www.congress.gov/bill/119th-congress/house-bill/3633) and other official information from the government of the United States, however other credible reporting may be used.
Market Opened: Jul 15, 2026, 3:28 PM ET
Resolver
0x65070BE91...The existence of any carve-outs or exceptions shall not be relevant for purposes of this market.
The primary resolution source is Congress.gov’s legislation tracker (https://www.congress.gov/bill/119th-congress/house-bill/3633) and other official information from the government of the United States, however other credible reporting may be used.
Resolver
0x65070BE91...The House passed the Sunshine Protection Act (H.R. 139) on July 14, 2026, by a 308-117 bipartisan vote, advancing permanent daylight saving time with state opt-out provisions and receiving President Trump's endorsement. The measure was referred to the Senate Commerce Committee the next day, where the companion bill remains stalled without further action. Historical precedent shows repeated congressional failures despite similar momentum, compounded by sleep medicine opposition citing circadian health risks and a compressed legislative calendar before the end of 2026. Trader consensus reflected in the 72.5% "No" probability accounts for these Senate procedural and timing barriers, even as 19 states maintain conditional statutes awaiting federal authorization.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions